Optimal Treatment Duration of Neoadjuvant Endocrine Therapy for Women Aged 60 Years or Older with Estrogen Receptor-Positive, HER2-Negative Invasive Breast Cancer

Yuji Hayashi1,2, Hiroyuki Takei2,3, Tsuyoshi Saito1, Toshihiro Kai1, Kenichi Inoue4, Masafumi Kurosumi5, Jun Ninomiya6,8 and on behalf of Saitama Breast Cancer Clinical Study Group (SBCCSG)

1Department of Breast Surgery, Japanese Red Cross Saitama Hospital, Saitama, Japan
2Division of Breast Surgery, Saitama Cancer Center, Saitama, Japan
3Department of Breast Surgery and Oncology, Nippon Medical School, Tokyo, Japan
4Shintoshin Ladies’ MammoClinic, Saitama, Japan
5Division of Breast Oncology, Saitama Cancer Center, Saitama, Japan
6Department of Pathology, Kameda Kyobashi Clinic, Tokyo, Japan
7Department of Pathology, Saitama Cancer Center, Saitama, Japan
8Ninomiya Hospital, Saitama, Japan

Background: Neoadjuvant endocrine therapy is not the standard of care for breast cancer, primarily because the optimal treatment duration remains unclear. This phase 2 prospective multicenter study analyzed time to progression, time to maximal response, and time to treatment failure for neoadjuvant exemestane.

Methods: Inclusion criteria were women aged ≥60 years with Stage II or III breast cancer classified as estrogen receptor-positive/human epidermal growth factor receptor 2-negative. Response was defined as a ≥10% and minimum of 3 mm decrease in tumor size, as compared with the most recent or smallest value, and no new lesion. Progression was defined as a >10% and minimum of over 3 mm increase in tumor size, as compared with the most recent or smallest value, or a new lesion. Maximal response was defined as the final recorded response.

Results: This study included 24 women, most of whom had T2 N0 tumors with high estrogen receptor expression. We initially observed a response in 23 patients (96%); however, 6 patients (25%) later experienced progression. Time to progression, time to maximal response, and time to treatment failure ranged from 7 to 22 months (estimated median, 35), 1 to 22 months (estimated median, 10), and 2 to 22 months (estimated median, 22), respectively. Treatment duration varied widely, but the estimated optimal duration of neoadjuvant exemestane therapy was 22 to 35 months in patients seeking to avoid surgery and 10 months in patients wishing to receive breast-conserving surgery.

Conclusions: Neoadjuvant exemestane therapy is long effective for older women with hormone-sensitive breast cancer. (J Nippon Med Sch 2021; 88: 354-360)

Key words: neoadjuvant endocrine therapy, aromatase inhibitors, exemestane, progression, response

Introduction

In women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer, initial endocrine therapy (ET) is a standard treatment. In metastatic, non-curable diseases, it is generally considered that ET is better than chemotherapy because quality of life is meaningful, with no clear evidence that initial chemotherapy can prolong sur-
vival as compared with ET. In postmenopausal women with operable breast cancer, preoperative or neoadjuvant endocrine therapy (NET) is a treatment choice because in neoadjuvant settings aromatase inhibitors (AIs) were as effective as chemotherapy in terms of breast-conserving surgery (BCS) rates. In addition, the efficacy of neoadjuvant AIs was superior to that of tamoxifen.

In most previous studies, preplanned treatment durations of NET were 3 to 6 months; however, it was reported that some study patients continued to take AIs because of persistent tumor regression. Our Saitama Breast Cancer Clinical Study Group (SBCCSG) conducted a phase II clinical trial (SBCCSG-03) in which the pathological effects of exemestane were analyzed in postmenopausal women with ER-positive, invasive breast cancer after 4 months of treatment. A total of 44 patients were treated with neoadjuvant exemestane for 4 months; however, 6 chose to remain on exemestane without surgery because of estimated persistent tumor shrinkage.

NET is not a standard of care for breast cancer, because its optimal treatment duration has not been determined. In addition, it remains to be clarified whether survival times are improved by NET. The meaning of “optimal” depends on the purpose of treatment. The main purpose of NET is converting an initially necessary mastectomy to BCS. In this setting, optimal treatment duration is identical to time to maximal response (TTMR). Another purpose of NET is to safely avoid surgery during a certain period without progression. For this purpose, optimal treatment duration is identical to time to progression (TTP). TTP is an important index when surgery must be postponed. The last purpose is to discern the sensitivity of ET, which implies prediction of survival time and determination of chemotherapy requirements. TTP is a clinical marker believed to correlate with the sensitivity of ET.

For optimal treatment durations of NET using AIs, TTPR and the time to maximize a conversion rate of mastectomy to BCS were analyzed in previous studies, whereas, TTP has never been analyzed. Because the optimal treatment duration for adjuvant ET is 5 years or more, the median TTP of NET might be much longer than the planned treatment durations in previous studies. A phase II multicenter study conducted by SBCCSG analyzed TTP, TTMR, and time to treatment failure (TTF) of NET using the steroidal AI exemestane in women aged 60 years or older with ER-positive, HER2-negative invasive breast cancer. This article is the first report of this study.

**Patients and Methods**

**Trial Design**

This phase II, multicenter trial of SBCCSG-10 analyzed optimal treatment durations for neoadjuvant exemestane (trial identification, UMIN000000802). The primary endpoint was TTP. Secondary endpoints were TTMR, TTF, clinical tumor response (Response Evaluation Criteria in Solid Tumors, RECIST, version 1.1), pathological tumor response, adverse events, changes in bone mineral density, and changes in Ki67 labeling index. The treatment plan involved neoadjuvant use of exemestane for at least 3 years, unless progression was observed. This trial was approved by the institutional review boards of all hospitals in which patients were recruited. In this manuscript, TTP, TTMR, and TTF were analyzed based on tumor size, as measured by a caliper at preplanned time points.

**Patients**

Eligible patients were women aged 60 years or older with core needle biopsy-proven, ER-positive, and HER2-negative invasive carcinoma of the breast, without distant metastases. Eligibility criteria for clinical tumor size and clinical nodal status were T2, T3, or T4b and N0, N1, or N2, respectively, according to the UICC TNM classification. ER positivity was defined as 10% or more positive cells by immunohistochemistry (IHC). HER2 negativity was defined as 0, 1+, or 2+ by the HercepTest; however, 2+ cases with HER2 amplification >1.8 HER2/chromosome 17 centromere (CEP17) ratio by fluorescence in situ hybridization (FISH) were excluded. Eligible performance status (Eastern Cooperative Oncology Group, ECOG) was 0 to 1. Written informed consent was required for all patients.

Exclusion criteria were patients who had received chemotherapy or ET for the present disease, patients who were receiving hormone replacement therapy at diagnosis, and patients who had a previous history of breast cancer or any active invasive cancers.

A total sample size of 23 was determined for this study based on the following analysis. In the SBCCSG-03 trial, a partial response or a minor response was observed in 86% of postmenopausal women with ER-positive invasive breast cancer at 4 months after starting neoadjuvant exemestane. If the effects of neoadjuvant exemestane were consistent with an exponential distribution, the estimated progression-free survival (PFS) rate would be 25% at 3 years. In this trial, the recruited patients were considered more sensitive to neoadjuvant exemestane because they were older than patients in the SBCCSG-03 trial and because HER2-positive disease was
Y. Hayashi, et al

Table 1  Patient and tumor characteristics

| Age, years | N |
|-----------|---|
| 60-84 (mean and median, 69) | |

| TNM Stage | |
|-----------|---|
| T2 N0 | 20 (91.7%) |
| T2 N1 | 2 (8.3%) |
| T4b N0 | 1 (4.2%) |
| T4b N2 | 1 (4.2%) |

| ER/PgR (0-8, Allred score; +, Score unknown) | |
|---------------------------------------------|---|
| ER 7-8/PgR 7-8 | 11 (45.8%) |
| ER 7-8/PgR 5-6 | 3 (12.5%) |
| ER 7-8/PgR 0-4 | 9 (37.5%) |
| ER+/PgR+ | 1 (4.2%) |

| HER2 | |
|------|---|
| 2+ (FISH<1.8) | 2 (8.3%) |
| 1+ | 14 (58.3%) |
| 0 | 8 (33.3%) |

The first patient was registered in August 2007, and a total of 25 patients were registered as of February 2009, when study entry was closed.

**Treatment and Follow-up**

Patients took exemestane 25 mg per day for at least 3 years after starting the treatment, unless progression was observed. The follow-up period was defined as the interval from the beginning of treatment to the last outpatient visit or death from any cause.

**Clinical Tumor Response**

Tumor size was measured by palpation by using a caliper at baseline, at 1, 2, and 3 months after starting treatment, and every 3 months thereafter. Ultrasound and/or mammography were performed at baseline, at 3 and 6 months after starting treatment, and every 6 months thereafter. Tumor size was defined as maximum tumor diameter.

A response was defined as a decrease of ≥10% and minimum of 3 mm in tumor size, as compared with the most recent or smallest value, and no new lesions. Progression was defined as an increase of >10% and minimum of over 3 mm in tumor size, as compared with the most recent or smallest value, or a new lesion. No change was defined as a finding outside the above categories. Maximal response was defined as the final recorded response. For tumors that were no longer palpable, tumor size was categorized as 0 mm and defined as maximal response. Tumor response was also classified into 4 categories-complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD)-by RECIST version 1.1. Response was categorized as CR when tumors were nonpalpable.

**TTP, TTMR, and TTF**

TTP and TTMR were defined as the durations from the beginning of treatment to progression and maximal response, respectively. TTF was defined as the duration from the beginning of treatment to the time treatment was stopped for any reason. TTP, TTMR, and TTF were calculated in all patients. The medians of these durations were calculated by the Kaplan-Meier method. Statistical analyses were performed by using BellCurve for Excel (SSRI, Inc. Japan).

**Results**

Twenty-five patients were initially registered in this trial. However, 1 was ineligible because she had a tumor with 2+ HER2 expression by HercepTest and 1.9 ratio of HER2 amplification by FISH. Ultimately, 24 patients with 24 tumors were eligible for this study. Patient age was 60 to 84 years (mean and median, 69.0 years). Tumor size by palpation at baseline was 23 to 50 mm (mean, 33.6 mm). Tumor size, nodal status, ER, progesterone receptor (PgR), and HER2 at baseline are shown in Table 1. Most patients were classified as T2 N0 M0, stage IIA, and tumors had high ER expression.

Tumor size as measured by palpation at preplanned time points was analyzed because some ultrasound and mammography data were missing. Of the 24 patients, a response was initially observed in 23 (96%) at 1 to 6 months after starting treatment. No change was observed in 1 patient (4%) until 15 months after starting treatment. Tumor size in relation to baseline tumor size was calculated for each patient at all time points. Mean relative tumor size consistently decreased over time during the entire study period (Fig. 1).

Progression was observed in 6 patients (25%), all of whom had an initial response. Time range to progression after starting treatment was 7 to 22 months (Fig. 2). In one of the 6 patients, a new lesion was detected in the same breast at 22 months after starting treatment and was classified as progression, although the primary tumor had become nonpalpable. This new lesion was pathologically diagnosed as ER-negative ductal carcinoma in situ. In the other 5 patients, all tumor sizes were excluded from the SBCCSG-03 trial. Therefore, PFS at 3 years was estimated to be 50% in this trial. To confirm this estimated PFS rate of 50%, 20 patients were required statistically, and the alpha error and beta error were 0.05 and 0.20, respectively. The number of patient withdrawals was estimated at 20%; thus, a total of 25 patients were needed for this trial.

The first patient was registered in August 2007, and a total of 25 patients were registered as of February 2009, when study entry was closed.
smaller than at baseline, even at the time of progression. No patient developed metastasis to the axilla or distant organs before primary tumor progression. In the 6 patients with progression, 5 underwent surgery and 1 declined surgery because advanced ovarian cancer was detected at the time of progression. Median TTP was not determined; however, from the fitted curve, it was estimated to be about 35 months (Fig. 2). One-year and 2-year PFS rates were 95% and 60%, respectively (Fig. 2). The 3-year PFS rate was estimated to be 50% from the fitted curve (Fig. 2). The 3-year PFS rate of 50% was identical to the estimate made when the study was designed and the sample size was calculated.

Among the 24 patients, maximal response was identified in 18 (75%). In 3 of these 18 patients, the tumors became nonpalpable. TTMR was 1 to 22 months after initiation of treatment (Fig. 3). Median TTMR was 11.9 months, by the Kaplan-Meier method, and about 10 months, according to the fitted curve estimate (Fig. 3).

The neoadjuvant exemestane was discontinued in 13 patients (54%) because of progression (n = 6), patient preference (n = 5), and adverse events (n = 2). The adverse events were eczema in 1 patient, and arthralgia and amnesia in 1 patient. The TTF was 2 to 22 months after treatment initiation (Fig. 4). Median TTF was 17.9 months, and the fitted curve estimate was 22 months (Fig. 4). Of the 13 patients who discontinued treatment, 12 underwent surgery, but 1 patient with advanced ovarian cancer diagnosed at the time of progression (mentioned above) did not. Of the 12 patients who underwent surgery, 11 (92%) underwent partial mastectomy and 1 (8%) total mastectomy.

According to the RECIST, CR, PR, and SD were the best response in 3 (13%), 14 (58%), and 7 (29%) patients, respectively. PD was observed in 6 patients (25%).

Discussion

How long can NET safely delay surgery without worsening survival time? In theory, primary tumor cells probably do not metastasize while the tumor is shrinking during NET. Furthermore, NET, if it works, can kill metastatic tumor cells. Therefore, TTP is the duration when
surgery can be safely delayed. This hypothesis is supported by previous randomized controlled studies of women aged 70 years or older, for whom tamoxifen taken until disease progression had a survival benefit similar to that for surgery alone\textsuperscript{17}.

In this study, progression was observed in 6 (25%) of the 24 patients at 7 to 22 months after starting treatment, and median TTP was estimated to be 35 months (Fig. 2). Almost all patients initially responded to exemestane in this study, which suggests that de novo resistance is rare in patients who met the present inclusion criteria. Furthermore, TTP analysis showed that a relatively long interval is needed in order to acquire resistance to neoadjuvant exemestane. However, neoadjuvant exemestane was stopped for various reasons at 2 to 22 months after starting treatment, and median TTF was estimated to be 22 months (Fig. 4). Accordingly, the optimal treatment duration for which surgery can be safely delayed is estimated to be 22 to 35 months, which is a long but wide interval.

NET has the benefit of converting mastectomy to BCS in postmenopausal women\textsuperscript{2,6,8,14}. Generally, BCS is most suitable when a maximal response is observed. Llombart-Cussac et al\textsuperscript{12} reported that, in 70 patients preoperatively treated with letrozole for 4 to 12 months, median TTMR was 4.2 months, although 20 patients achieved maximal response within 6 to 12 months. Dixon et al\textsuperscript{9} reported that, in patients taking neoadjuvant letrozole, tumor volume continued to decrease between 3 and 6 months (median 50%), 6 and 12 months (median 37%), and 12 and 24 months (median 33%). These results indicate that, in relatively large populations of patients, tumors continued shrinking for 12 to 24 months. In our study, TTMR ranged from 1 to 22 months (median, 10 months; Fig. 3). The results of previous studies strongly support the present results.

Previous studies of BCS rates and treatment duration for neoadjuvant AIs found that BCS rates did not differ for 4 months and >4 months\textsuperscript{11,13}. However, another study showed that BCS rates increased from 60% to 72% in patients who continued treatment for longer than 3
months\textsuperscript{44}. Furthermore, a multicenter trial of neoadjuvant AI found that median time to BCS was 7.5 months\textsuperscript{42}. On the basis of the above results, neoadjuvant AIs required at least 4 or 7.5 months to maximize the BCS rate. The main purpose of BCS is to control local recurrence and achieve a good aesthetic result. The former depends on the surgical margin status and the latter on the volume of breast tissue removed. To achieve negative surgical margins when removing a smaller volume of breast tissue, surgery should be performed at the time of maximal response to NET. All these results, including ours, suggest that the optimal treatment duration to become suitable for BCS was 4 to 10 months; however, the treatment window was wide. For the most appropriate BCS to be performed, it is important to closely monitor tumor size during NET.

One of purpose of NET is to discern the sensitivity of ET. Sensitivity implies prediction of survival time and determination of chemotherapy requirements. High ER and PgR expressions, negative HER2, and reduction in the Ki67 labeling index are considered surrogate markers of higher sensitivity to NET\textsuperscript{19}. In previous analyses of survival time, disease-free survival time was predicted by the Ki67 labeling index at 2 to 4 weeks\textsuperscript{21,22} and 3 to 4 months after starting NET. TTP, as defined in this study, is a candidate clinical marker to predict NET sensitivity. Shorter TTP likely correlates with worse survival rates when ET alone is administered, even after tumor progression. In this study, however, survival times were not analyzed in correlation with the TTP. Generally, chemotherapy is recommended in patients whose tumors progress during NET. In conclusion, the present benefits indicate that neoadjuvant exemestane is a long effective strategy for older women with hormone-sensitive breast cancer.

Contributions: All authors made substantial contributions to the study, have approved the current version, and have consented to publication.

Acknowledgement: We would like to thank Editage (www.editage.com) for English language editing.

Funding: This study was supported in part by Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science.

Conflict of Interest: Dr. Takei reports personal fees and non-financial support from Pfizer, during the conduct of the study; grants and personal fees from Chugai Seiyaku, Inc.; grants and personal fees from Taiho Yakuhin, Inc.; grants and personal fees from Daichi Sankyo, Inc.; grants and personal fees from Takeda Yakuhin Kogyo, Inc.; grants and personal fees from Eisai, Inc.; grants from Fuji Film Toyama Kagaku, Inc., outside the submitted work. Dr. Inoue reports grants and personal fees from Pfizer during the conduct of the study; grants

Neoadjuvant Endocrine Therapy for Breast Cancer
from Novartis; grants and personal fees from Chugai; grants and personal fees from Eli Lilly; grants from Daiichi-Sankyo; grants from Parexel/Puma Biotechnology; grants from MSD; grants from Astra-Zeneca; grants from Sanofi, outside the submitted work. Dr. Saito reports personal fees from Pfizer during the conduct of the study; personal fees from Chugai Seiyaku, Inc.; personal fees from Nihon Kayaku, Inc.; personal fees from Novartis Pharma, Inc.; personal fees from Eisai, Inc.; personal fees from Taiho Yakuhun Kogyo, Inc.; personal fees from Astra Zeneca, outside the submitted work. Dr. Kurosumi reports personal fees from Chugai Seiyaku, Inc. and Taiho Yakuhun during the conduct of the study, outside the submitted work. The other authors report no conflict of interest.

References

1. Iwase H. Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor. Int J Clin Oncol. 2015;20:249–52. doi: 10.1007/s10147-015-0795-6

2. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007;110:244–54. doi: 10.1002/cncr.22789

3. Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study. Ann Oncol. 2012;23:3069–74. doi: 10.1093/annonc/mds132

4. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–16. doi: 10.1200/JCO.2001.19.18.3808

5. Smith IE, Dowsett M, Ebbs SR, et al. IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–16.

6. Cataliotti L, Buzdar AU, Noguchi S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative ‘Arimidex’ Compared to Tamoxifen (PROACT) trial. Cancer. 2006;106:2095–103. doi: 10.1002/cncr.21872

7. Takei H, Kurosumi M, Yoshida T, et al. Preoperative endocrine therapy of breast cancer: which patients would benefit and what are the advantages? Breast Cancer. 2011;18:85–91.

8. Arthur LM, Turnbull AK, Khan LR, Dixon JM. Pre-operative Endocrine Therapy. Curr Breast Cancer Rep. 2017;9:202–9. doi: 10.1007/s12699-017-0255-6

9. Dixon JM, Renshaw L, Macaskill EJ, et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole. Breast Cancer Res Treat. 2009;113:145–51. doi: 10.1007/s10549-008-9915-6

10. Takei H, Suematsu K, Inoue K, et al. Saitama Breast Cancer Clinical Study Group. Multicenter phase II trial of preoperative exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03). Breast Cancer Res Treat. 2008;107:87–94.

11. Krainick-Strobel UE, Lichtenegger W, Wallwiener D, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer. 2008;8:62.

12. Llombart-Cussac A, Guérrero A, Galán A, et al. Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/FgR [+ ] operable breast cancer. Clin Transl Oncol. 2012;14:125–31. doi: 10.1007/s12974-012-0771-9

13. Hojo T, Kinoshita T, Imoto S, et al. Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy. Breast. 2013;22:263–7. doi: 10.1016/j.breast.2013.03.002

14. Fontein DB, Charehdari A, Nortier J, et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients— a phase II trial. Eur J Cancer. 2014;50:2190–200. doi: 10.1016/j.ejca.2014.05.010

15. Burstein HJ, Lachetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37:423–38. doi: 10.1200/JCO.18.01160

16. Eisehauera EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi: 10.1016/j.ejca.2008.10.026

17. Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;(1):CD004272. doi: 10.1002/14651858. CD004272.pub2

18. Carpenter R, Dougherty JC, Cordiner C, et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery. Breast Cancer Res Treat. 2014;144:569–76. doi: 10.1007/s10549-014-2835-8

19. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007;99:167–70. doi: 10.1093/jnci/djk020

20. Ellis MJ, Suman VJ, Hoag J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017; 35:1061–9. doi: 10.1200/JCO.2016.69.4406

21. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008;100:1380–8. doi: 10.1093/jnci/djp309

22. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G, Miller WR. The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res. 2010;16:2229–35.

(Received, August 13, 2020)
(Accepted, October 28, 2020)

(J-STAGE Advance Publication, November 30, 2020)